10.18
-0.29 (-2.77%)
| Previous Close | 10.47 |
| Open | 10.45 |
| Volume | 50,698 |
| Avg. Volume (3M) | 1,936,779 |
| Market Cap | 1,722,618,496 |
| Price / Sales | 5.44 |
| Price / Book | 1.91 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Operating Margin (TTM) | -4,568.83% |
| Diluted EPS (TTM) | -4.23 |
| Quarterly Revenue Growth (YOY) | -94.60% |
| Total Debt/Equity (MRQ) | 9.21% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | -415.08 M |
| Levered Free Cash Flow (TTM) | -310.09 M |
| Return on Assets (TTM) | -23.52% |
| Return on Equity (TTM) | -44.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vir Biotechnology, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.67 |
Select this tab to load the latest available analysis.
|
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 10.57% |
| % Held by Institutions | 79.54% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |